Press Release June 08, 2020

Pliant Therapeutics Closes $165.6 Million IPO and Full Exercise of Option to Purchase Additional Shares

The Life Sciences practice advised Pliant Therapeutics, Inc. (Nasdaq: PLRX), on its $165.6 million initial public offering of 10,350,000 shares of common stock, which includes the exercise in full by the underwriters of their 30-day option to purchase up to an additional 1,350,000 shares of common stock, at a public offering price of $16.00 per share. 
 
Pliant is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis.
 
The Goodwin team was led by Sam Zucker, Deepa Rich and James Xu, and included Andrew Whitworth, Julie Tibbets, Elizabeth Mulkey, Roger Cohen, Crescent Chasteen, Grace Wirth, Dan Karelitz, Matt DunayEttore Santucci, Robert Dzialo, James Matarese, and Nathan Needle, with invaluable paralegal assistance from, Tricia Hojo and Ruowen Li.
 
For more details, read the press release and articles in Law360, FierceBiotech, and Silicon Valley Business Journal.